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Abstract
Background: Although the medical outcomes of antiretroviral therapy (ART) for HIV/AIDS are well described, less is known
about how ART affects patients’ economic activities and quality of life, especially after the first year on ART. We assessed
symptom prevalence, general health, ability to perform normal activities, and employment status among adult antiretroviral
therapy patients in South Africa over three full years following ART initiation.
Methodology/Principal Findings: A cohort of 855 adult pre-ART patients and patients on ART for ,6 months was enrolled
and interviewed an average of 4.4 times each during routine clinic visits for up to three years after treatment initiation using
an instrument designed for the study. The probability of pain in the previous week fell from 74% before ART initiation to
32% after three years on ART, fatigue from 66% to 12%, nausea from 28% to 4%, and skin problems from 55% to 10%. The
probability of not feeling well physically yesterday fell from 46% to 23%. Before starting ART, 39% of subjects reported not
being able to perform their normal activities sometime during the previous week; after three years, this proportion fell to
10%. Employment rose from 27% to 42% of the cohort. Improvement in all outcomes was sustained over 3 years and for
some outcomes increased in the second and third year.
Conclusions/Significance: Improvements in adult ART patients’ symptom prevalence, general health, ability to perform
normal activities, and employment status were large and were sustained through the first three years on treatment. These
results suggest that some of the positive economic and social externalities anticipated as a result of large-scale treatment
provision, such as increases in workforce participation and productivity and the ability of patients to carry on normal lives,
may indeed be accruing.
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Introduction
By late 2008, some 2.9 million people in sub-Saharan Africa
were receiving antiretroviral therapy for HIV/AIDS[1]. A large
body of literature confirms the success of AIDS treatment
programs in reducing viral loads and restoring the immune
systems of adult patients in sub-Saharan Africa[2–6]. Long-term
survival rates remain high despite some concerns about long-term
retention of patients in treatment programs[7].
Alongside these studies of biomedical outcomes of treatment is a
small body of literature investigating the impacts of ART on
patients’ economic activities, quality of life, and other non-
biomedical outcomes during the first year on treatment. These
studies, which have recently been reviewed[8], have consistently
reported rapid and relatively large improvements in quality of life
and/or work attendance during the first year on ART among
adult patients in Africa. After 12 months on ART, for example,
large proportions of patients participating in a prospective cohort
study in Cape Town, South Africa reported improvements in all
domains assessed, which included self-care, usual activities, pain/
discomfort, and anxiety/depression[9]. Similarly, after 12 months
on ART, patients enrolled in a prospective cohort in Uganda
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role function, general health perceptions, mental health, physical
health, and depression[10].
What has been missing so far is evidence about the longer-term
sustainability of these improvements beyond the initial year on
treatment. Sustained improvements in economic and quality of life
outcomes are likely to support long-term adherence and to
mitigate some of the negative economic and social consequences of
untreated HIV/AIDS in high-prevalence countries. In this paper,
we report results of a longitudinal study of South African ART
patients who have been followed for up to three years after starting
treatment. Outcomes analyzed include self-reported ability to
perform normal daily activities, prevalence of symptoms, and
employment status in the first 1080 days after ART initiation.
Methods
Ethics statement
The study was approved by the Institutional Review Board of
the Boston University Medical Campus and the Human Research
Ethics Committee (Medical) of the University of the Witwaters-
rand. Written informed consent was provided by all study subjects.
Study sites
The study was conducted at three ART clinics in South Africa.
The cohort and study methods have been described previous-
ly[11–13]. The first site, the Themba Lethu Clinic of Helen Joseph
Hospital in Gauteng Province, is a large, urban, public referral
hospital which had 9,600 adult patients on ART as of September
2009. The other two sites are nongovernmental clinics. The
Witkoppen Health and Welfare Centre is a full service, primary
care clinic serving informal peri-urban settlements in Gauteng
Province. ACTS Clinic is a dedicated HIV/AIDS clinic in a rural
setting in Mpumalanga Province. As of September 2009, these two
sites had approximately 2,700 and 2,400 adult patients on ART,
respectively.
All three sites followed the 2004 South African national
guidelines for providing HIV/AIDS care and treatment. Under
these guidelines, ART was initiated once a patient’s CD4 count fell
to less than 200 cells/mm
3 or WHO Stage IV disease was
diagnosed, though many patients first presented at the study clinics
with CD4 counts far below 200 Most patients were initiated on the
national first-line regimen of stavudine, lamivudine, and efavirenz
or nevirapine. Patients not yet eligible for treatment were
monitored and received counseling and vitamin supplements.
Sample selection and data collection
At each site, study subjects were identified each day from
patients present at the clinic, either waiting in a queue or attending
an adherence or wellness class or support group. We selected
subjects from these groups (queue, class, or support group) using
nth-name sampling and invited them to participate in the study.
Adult patients who were HIV-positive but not yet medically
eligible for ART or who had initiated ART less than six months
before recruitment were eligible for enrollment. Those who
provided written informed consent were enrolled in the cohort
and administered a baseline questionnaire by a study interviewer.
Enrollment took place between June 2005 and June 2006.
Follow-up questionnaires were then administered as often as
possible when subjects returned for consultations or to pick up
medications. Because clinic visits were often unplanned and not all
subjects had time to participate in an interview at every visit,
interviews occurred at only a fraction of total visits and at irregular
intervals, as is discussed further below. In addition, subjects’
medical records were reviewed and information collected about
date of ART initiation, dates of clinic visits, CD4 counts, and other
indicators. For this analysis, data were censored on September 30,
2009.
Outcome variables
The questionnaire was designed for this study and focused on
subjects’ self-reported health conditions and engagement in
Figure 1. Study subject recruitment and inclusion for analysis.
doi:10.1371/journal.pone.0012731.g001
Table 1. Characteristics of cohort at baseline.
Variable Value
N8 5 5
Female (%) 662 (77%)
Age at enrollment (%)
18–29 years 242 (28%)
30–39 years 402 (47%)
40–49 years 160 (19%)
.49 years 51 (6%)
Median CD4 count closest to treatment initiation
(cells/mm
3) [IQR]
105 [37–161]
Primary activity when feeling well enough to
perform normal activities, at study enrollment (n (%))
Employed in formal sector 217 (25%)
Work in informal sector or self-employed 166 (19%)
Unemployed, seeking work 204 (24%)
Housework or family care (unpaid) 223 (26%)
Other (studying, retired, leisure, service, missing) 45 (5%)
doi:10.1371/journal.pone.0012731.t001
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investigated. Four are related to specific symptoms: pain or
headache, nausea, tiredness or fatigue, and skin rash or other skin
problems. Because these symptoms affect a person’s ability to
perform normal activities, these outcomes have economic as well
as quality-of-life implications. Two outcomes are related to general
health condition and asked whether the subject did not feel well
physically at least part of the day yesterday or whether the subject
felt sad, depressed, or stressed at least part of the day yesterday.
Finally, three outcomes pertained to normal activities and
employment status. Inability to perform normal activities was
defined as reporting being unable to perform one’s normal
activities for at least part of a day in the previous five-day work
week (Monday-Friday) due to physical or mental health. When
subjects reported any inability to perform normal activities, the
number of days to which this pertained in the same five-day period
was elicited. The employment status variable was defined as
holding a full time or part time wage or salary position, including
domestic service but excluding informal sector piecework activi-
ties. Although many of our outcomes overlap with definitions in
the World Health Organization’s International Classification of
Functioning, Disability and Health (ICF)[14], for this study
multiple ICF classifications were collapsed into a few more
broadly-defined outcomes.
Statistical analysis
Information from the nine outcomes was organized into 8
dichotomous variables (1=yes, 0=no) and one continuous variable
(days unable to perform normal activities in previous work week,
between 0 and 5). For each interview for each study subject who
initiated ART prior to June 2009, the interview date was compared
to the date the subject initiated therapy to calculate the number of
days on ART at each interview. The date of ART initiation was
extractedfrom the subject’s clinical records. Timeon ART, from 90
days before initiation ART to 1080 days after, was stratified into
thirteen90-dayincrements.Inrecognitionthatchangesinwellbeing
may be more rapid immediately after initiating treatment, the first
90-day period was further subdivided into days 0–30 and 31–90 on
ART, for a total of 14 separate time-on-ART dummy variables.
A logistic regression framework was used to estimate the
probability (absolute risk) that a subject reported yes for each
dichotomous outcome, with data pooled across the three study sites.
Linear regression was used for the number of days of unable to
perform normal activities. A population-averaged model for all
outcomes was used to account for multiple observations on a single
subject (using xtlogit and xtreg in STATA 10 with the pa option). In
each model, variables included three age categories (18–29, 40–49,
50+), sex (male=1, female=0), and 13 time-on-ART dummy
variables. The reference age category variable was 30–39 years of age
and the reference time-on-ART variable was the initial 30 days on
ART (days 0–30). Other than for the employment status outcome,
significant site effects were not found, so site was not included as a
variable in the models. For the employment status outcome, the site-
specific estimates are discussed in the results section.
Using the logistic regression results, we computed the estimated
probability for each outcome for the reference case representing
the largest age/sex group in the sample (female, aged 30–39)
during the first month on ART (0–30 days on ART). We then
estimated marginal/partial effects for each covariate in the logistic
model (other age categories, male instead of female, and the 13
time-on-ART dummy variables) using the mfx post-estimation
command in STATA 10. Odds ratios from the logistic regression
model are not reported but available from the authors. Finally, we
performed Wald tests for linear hypotheses about the parameters
of the logistic regression model to investigate if the changes
observed after 360 days on ART were sustained over the next two
years (using the post-estimation test command in STATA 10.1).
Results
Cohort recruitment and baseline characteristics
The cohort was enrolled between July 1, 2005 and June 30,
2006. Study recruitment and the construction of the analytic
cohort are shown in Figure 1. Characteristics of the cohort at
baseline have been described previously[12,13]. At baseline, the
Figure 2. Mean CD4 cell counts of study cohort and clinic population by time on ART.
doi:10.1371/journal.pone.0012731.g002
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started ART and 616 had been on ART for less than 6 months. At
the time of censoring for data analysis, 57% of the original cohort
of 1,065 subjects were still attending the study clinics and had been
interviewed at least once within the previous 12 months; 8% were
still attending the study clinics but had not been interviewed within
the previous 12 months (study loss to follow up); 22% were no
longer attending the study clinics for unknown reasons (program
loss to follow up); 7% had transferred to a different treatment
facility; and 5% had died.
Table 2. Reference probability and marginal effects of experiencing pain or fatigue during the previous week (logistic regression,
population averaged model).
Variable Marginal effect Probability p-value
95% confidence interval for
marginal effect
Outcome: Pain last week
Reference case estimated probability =0.543*
sex (male) 20.104 43.9% 0.000 [20.156,20.052]
18–29 years old 20.053 49.0% 0.038 [20.103,20.003]
40–49 years old 0.082 62.5% 0.003 [0.028,0.136]
50+ years old 0.066 60.9% 0.123 [20.018,0.150]
290 to 21 days 0.201 74.4% 0.000 [0.109,0.293]
0 to 30 days (reference) * 54.3% * *
31–90 days 20.038 50.5% 0.397 [20.126,0.050]
91–180 days 20.052 49.1% 0.193 [20.131,0.026]
181–270 days 20.024 51.9% 0.589 [20.110,0.062]
271–360 days 20.076 46.7% 0.087 [20.162,0.011]
361–450 days 20.098 44.5% 0.026 [20.184,20.012]
451–540 days 20.133 41.0% 0.003 [20.221,20.045]
541–630 days 20.135 40.8% 0.003 [20.224,20.045]
631–720 days 20.178
a 36.5% 0.000 [20.264,20.093]
721–810 days 20.278 26.5% 0.000 [20.357,20.199]
811–900 days 20.189 35.4% 0.000 [20.267,20.110]
901–990 days 20.25 29.3% 0.000 [20.327,20.173]
991–1080 days 20.220
a 32.3% 0.000 [20.297,20.142]
Outcome: Fatigue last week
Reference case estimated probability =0.498
sex (male) 20.068 43.0% 0.021 [20.126,20.01]
18–29 years old 0.004 50.2% 0.894 [20.051,0.059]
40–49 years old 0.035 53.3% 0.283 [20.028,0.098]
50+ years old 0.054 55.2% 0.265 [20.041,0.15]
290 to 21 days 0.158 65.6% 0.002 [0.06,0.256]
0 to 30 days (reference) * 49.8% * *
31–90 days 20.023 47.5% 0.614 [20.111,0.066]
91–180 days 20.17 32.8% 0.000 [20.247,20.092]
181–270 days 20.171 32.7% 0.000 [20.254,20.087]
271–360 days 20.226 27.2% 0.000 [20.309,20.144]
361–450 days 20.241 25.7% 0.000 [20.323,20.160]
451–540 days 20.249 24.9% 0.000 [20.332,20.166]
541–630 days 20.275 22.3% 0.000 [20.358,20.191]
631–720 days 20.292
b 20.6% 0.000 [20.371,20.212]
721–810 days 20.341 15.7% 0.000 [20.416,20.266]
811–900 days 20.328 17.0% 0.000 [20.402,20.254]
901–990 days 20.372 12.6% 0.000 [20.444,20.300]
991–1080 days 20.374
a 12.4% 0.000 [20.445,20.302]
*Reference case is a female subject age 30–39, 1–30 days on ART.
aIndicates p-value #0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.
bIndicates p-value .0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.
doi:10.1371/journal.pone.0012731.t002
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interview and September 30, 2009. During this period of
observation, 855 subjects initiated or were already on ART and
completed at least one interview after treatment initiation. The
remaining 210 study subjects had not yet started ART by their
final interview within this period or were not interviewed between
90 days before ART initiation and 1080 after and are not included
in this analysis. For the 855 subjects included, the average number
of interviews per subject was 4.4. Interviews were conducted
primarily during visits for purposes of medical consultation (59%)
or medication pickup (38%). The median [IQR] interval between
interviews was 170 [115–266] days.
Table 3. Reference probability and marginal effects of experiencing nausea or skin problems during the previous week (logistic
regression, population averaged model).
Variable Marginal effect Probability p-value
95% confidence interval for
marginal effect
Outcome: Nausea last week
Reference case estimated probability =0.231
sex (male) 20.018 21.3% 0.488 [20.069,0.033]
18–29 years old 0.018 24.9% 0.484 [20.033,0.070]
40–49 years old 0.028 25.9% 0.374 [20.033,0.089]
50+ years old 20.014 21.7% 0.759 [20.105,0.076]
290 to 21 days 0.048 27.9% 0.286 [20.040,0.137]
0 to 30 days (reference) * 23.1% * *
31–90 days 20.03 20.1% 0.423 [20.103,0.043]
91–180 days 20.107 12.4% 0.001 [20.169,20.044]
181–270 days 20.099 13.2% 0.004 [20.166,20.031]
271–360 days 20.097 13.4% 0.005 [20.164,20.029]
361–450 days 20.109 12.2% 0.001 [20.176,20.043]
451–540 days 20.136 9.5% 0.000 [20.202,20.071]
541–630 days 20.154 7.7% 0.000 [20.219,20.089]
631–720 days 20.168
a 6.3% 0.000 [20.231,20.106]
721–810 days 20.185 4.6% 0.000 [20.245,20.124]
811–900 days 20.181 5.0% 0.000 [20.241,20.122]
901–990 days 20.184 4.7% 0.000 [20.244,20.125]
991–1080 days 20.190
a 4.1% 0.000 [20.250,20.131]
Outcome: Skin problems last week
Reference case estimated probability =0.507
sex (male) 20.036 47.1% 0.230 [20.096,0.023]
18–29 years old 20.01 49.7% 0.725 [20.066,0.046]
40–49 years old 20.016 49.1% 0.631 [20.082,0.050]
50+ years old 20.039 46.8% 0.466 [20.142,0.065]
–90 to 21 days 0.041 54.8% 0.425 [20.060,0.142]
0 to 30 days (reference) * 50.7% * *
31–90 days 0.001 50.8% 0.979 [20.088,0.090]
91–180 days 20.122 38.5% 0.002 [20.201,20.043]
181–270 days 20.143 36.4% 0.001 [20.229,20.058]
271–360 days 20.173 33.4% 0.000 [20.259,20.087]
361–450 days 20.295 21.2% 0.000 [20.376,20.214]
451–540 days 20.325 18.2% 0.000 [20.406,20.244]
541–630 days 20.35 15.7% 0.000 [20.431,20.269]
631–720 days 20.405
a 10.2% 0.000 [20.480,20.330]
721–810 days 20.41 9.7% 0.000 [20.484,20.337]
811–900 days 20.42 8.7% 0.000 [20.491,20.348]
901–990 days 20.438 6.9% 0.000 [20.509,20.367]
991–1080 days 20.408
a 9.9% 0.000 [20.479,20.336]
*Reference case is a female subject age 30–39, 1–30 days on ART.
aIndicates p-value #0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.
doi:10.1371/journal.pone.0012731.t003
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at baseline. Most study subjects were women, which reflects the
preponderance of female patients at the site. Almost all were
economically active, either outside the home in formal (25%) or
informal (19%) employment or inside the home (26%) performing
housework or child care. Most of the rest (24%) were seeking
employment.
Most subjects initiated treatment at low CD4 counts (median
105 cells/mm
3). As Figure 2 illustrates, mean CD4 counts among
study subjects improved steadily as duration on treatment
increased. Figure 2 also indicates that the mean CD4 counts of
all patients initiated on ART at our largest study site, Themba
Lethu Clinic in Johannesburg, are similar to those of the study
cohort. Confidence intervals of the two groups overlap in the first
six months and after two years on treatment; between months 6
and 24, the difference between them is small, with the study
cohort’s mean slightly lower than that of the clinic population
overall.
Symptoms – fatigue, pain, nausea, and skin problems
Table 2 and Table 3 report the probability that subjects were
unable to perform their normal activities for at least part of a day
in the previous 7-day week as a result of each of four symptoms
(fatigue, pain, nausea, and skin problems). For each symptom, the
tables first report the estimated probability for the reference case
(female, aged 30–39, on ART for 0–30 days). For example, the
estimated probability of reporting pain for the reference case was
0.543 (54.3%). The following rows in the table report the marginal
effect or change in the estimated probability for each separate
variable included in the regression model, the probability for the
time interval, and the 95% confidence interval and associated p-
value for each marginal effect. For pain, the marginal effect for the
variable sex (male) is 20.104, leading to an estimated probability
of reporting pain of 0.543–0.104=43.9% for men, aged 30–39,
and on ART between 0 and 30 days.
The probabilities of each symptom for the reference case
(women, aged 30–39) over the 14 time categories are illustrated in
Figure 3. Declines in the probability of reporting physical
symptoms in the past week were significant (p-value #0.05) and
large for all four symptoms investigated (fatigue, pain, nausea, skin
problems). Improvements were sustained and or become larger
over the entire period of observation. The estimated probability of
pain for the reference case was 0.54. Prior to initiating ART (days
-90 to -1), the estimated probability of pain was substantially
higher, 0.74. Once ART was started, the declines estimated were
not significantly different from zero up to 360 days (i.e. the
probability of reporting pain in the previous week did not fall
during the initial year on therapy). By 720 days on ART, however,
the probability of experiencing pain in the previous week had
fallen to 0.36, a large and significant decline of 33% from baseline.
After three years, the probability had fallen further to 0.32, or 41%
below baseline. The probability after two years on ART was
estimated to be significantly lower than both the baseline and the
one year values. The estimated improvement in year two was
sustained through year three.
Fatigue, nausea, and skin problems showed a similar pattern of
ongoing improvement, with symptom probabilities falling by 80–
85% between 0–90 days before ART initiation and three years
after. Men were estimated to experience significantly less pain and
fatigue than women, but no sex differences were estimated in the
probability of nausea or skin problems.
General health on day preceding interview
Subjects were also asked two general questions about how they
felt on the day preceding the interview (did not fell well physically
yesterday for part or all of the day; felt sad, depressed, or stressed
yesterday for part or all of the day). Table 4 presents the logistic
regression model results, estimated marginal effects, and proba-
bilities for these two outcomes, and Figure 4 illustrates the
estimated probabilities for each outcome over time on ART.
The estimated probability that a subject reported feeling unwell
physically yesterday fell sharply over the first year on ART, from
0.40 to 0.22, an improvement that was sustained over the next two
years on therapy. The estimated probability of feeling sad,
Figure 3. Probability of experiencing symptoms last week by time on ART.
doi:10.1371/journal.pone.0012731.g003
Economic Outcomes on ART
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12731depressed, or stressed yesterday did not improve, however. While
the probability of this outcome at baseline (0–30 days) is
significantly lower than in the 90 days prior to treatment initiation,
there are no further estimated improvements that are sustained for
more than two time periods.
Normal activities and employment
Subjects were also asked about their ability to perform the
primary normal daily activities reported in Table 1 during the
previous five-day work week. If any inability was reported, then
the number of days was elicited. Table 5 reports results for both of
Table 4. Reference probability and marginal effects of feeling unwell on day before interview (logistic regression, population
averaged model).
Variable Marginal effect Probability p-value
95% confidence interval
for marginal effect
Outcome: Felt unwell physically yesterday (part or all of the day)
Reference case estimated probability =0.404
sex (male) 20.055 34.9% 0.030 [20.104,20.005]
18–29 years old 20.033 37.1% 0.186 [20.082,0.016]
40–49 years old 0.086 49.0% 0.003 [0.030,0.142]
50+ years old 0.081 48.5% 0.062 [20.004,0.166]
–90 to 21 days 0.054 45.8% 0.299 [20.048,0.155]
0 to 30 days (reference) * 40.4% * *
31–90 days 20.074 33.0% 0.092 [20.160,0.012]
91–180 days 20.127 27.7% 0.001 [20.204,20.050]
181–270 days 20.166 23.8% 0.000 [20.247,20.084]
271–360 days 20.186 21.8% 0.000 [20.267,20.106]
361–450 days 20.197 20.7% 0.000 [20.277,20.117]
451–540 days 20.222 18.2% 0.000 [20.302,20.142]
541–630 days 20.184 22.0% 0.000 [20.268,20.101]
631–720 days 20.176
b 22.8% 0.000 [20.257,20.094]
721–810 days 20.187 21.7% 0.000 [20.265,20.109]
811–900 days 20.19 21.4% 0.000 [20.265,20.114]
901–990 days 20.195 20.9% 0.000 [20.270,20.120]
991–1080 days 20.174
b 23.0% 0.000 [20.250,20.099]
Outcome: Felt sad, depressed, or stressed yesterday (all or part of the day)
Reference case estimated probability =0.236
sex (male) 20.018 21.8% 0.334 [20.056,0.019]
18–29 years old 20.011 22.5% 0.565 [20.048,0.026]
40249 years old 0.041 27.7% 0.078 [20.005,0.087]
50+ years old 0.064 30.0% 0.086 [20.009,0.136]
290 to 21 days 0.114 35.0% 0.017 [0.021,0.207]
0 to 30 days (reference) * 23.6% * *
31–90 days 0.028 26.4% 0.47 [20.049,0.105]
91–180 days 0.004 24.0% 0.899 [20.063,0.072]
181–270 days 20.035 20.1% 0.339 [20.107,0.037]
271–360 days 20.015 22.1% 0.692 [20.088,0.059]
361–450 days 20.035 20.1% 0.347 [20.107,0.038]
451–540 days 20.069 16.7% 0.057 [20.141,0.002]
541–630 days 0.001 23.7% 0.973 [20.076,0.079]
631–720 days 0.013
b 24.9% 0.737 [20.062,0.088]
721–810 days 20.035 20.1% 0.321 [20.104,0.034]
811–900 days 0.015 25.1% 0.678 [20.055,0.084]
901–990 days 0.043 27.9% 0.224 [20.026,0.113]
991–1080 days 0.076
a 31.2% 0.035 [0.005,0.146]
*Reference case is a female subject age 30–39, 0–30 days on ART.
aIndicates p-value #0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.
bIndicates p-value .0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.
doi:10.1371/journal.pone.0012731.t004
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part of a day in the previous week is illustrated in Figure 5. For the
reference case, this probability fell from 0.50 in the period
preceding the start of ART to approximately 0.21 after 1 year on
ART, 0.15 after two years on ART, and 0.11 by the end of three
years. There were no significant differences in this outcome
between males and females. Older patients were slightly more
likely to report this outcome.
Although the estimated probability of any inability to perform
normal activities in the previous week fell dramatically over the
first year on ART, the estimated average duration of inability for
those who reported any inability remained relatively long
regardless of time on ART. Conditional on any inability, the
estimated average number of days unable to perform normal
activities for the reference case is 3.03 days in the previous five
working days, or roughly 60% of the work week.
Finally, the results for employment status are reported in Table 6
and Figure 5. The estimated probability of having a job began to
increase after one and a half years on ART and remained
significantly higher, in the neighborhood of 45% of the cohort, for
the rest of the follow up period. The relatively long delay in seeing
a change in this indicator, rather than a large improvement during
the first year as with most other outcomes, may reflect the time
required to find employment once one becomes capable of
working. There is no indication that official unemployment in
South Africa fell during the study period; official unemployment
was 24.2% in March 2005[15], just before study recruitment
began, and 24.5% in September 2009[16], when data were
censored. The increase in employment observed for our cohort
over time on ART thus cannot be explained by improvements in
the broader labor market.
Unlike for other outcomes, employment status did vary by study
site. If Themba Lethu Clinic, the large urban public hospital in
Johannesburg, is used as the reference case, subjects enrolled at the
Witkoppen Health and Welfare Centre, which serves informal
settlements on the edge of Johannesburg, were 8% more likely to
report being employed, while those at the ACTS Clinic, a rural
site in Mpumalanga Province, were 7% less likely to report being
employed. For all sites, the basic trend over time on ART
remained essentially the same as shown in Figure 5.
Discussion
In a cohort of 855 adult patients on ART at three treatment
facilities in South Africa, indicators of well-being and economic
activity improved significantly within one year of treatment
initiation and either continued to improve or remained stable
for a full three years after starting treatment. For those patients
who remain on treatment, ART appears to offer long-term gains
in ability to perform normal activities, symptom prevalence, and
employment opportunities. The findings of this study suggest that
some of the positive economic and social externalities anticipated
as a result of large-scale treatment provision, such as increases in
workforce participation and productivity and the ability of patients
to carry on normal lives, may indeed be accruing.
By the end of the three-year observation period, the probability
of pain, fatigue, nausea, and skin problems reported by study
subjects had fallen by 57–85%. While pain and fatigue at three
years remained relatively common (reported by 32% and 12% of
subjects, respectively), these should be interpreted cautiously, as
some residual level of pain and fatigue is likely to be reported even
by a healthy, HIV-negative population. The probability of
reporting any inability to perform normal activities for reasons
of health during the preceding five-day work week fell to a stable
level of 10% of the cohort. For this core indicator of wellbeing, a
decline from almost 40% when initiating therapy to 10%
represents an important gain.
The study reported here has several limitations. First, it is an on-
treatment analysis only. The enrollment refusal rate was low (8%),
but post-enrollment loss to follow up from the cohort was high, for
a number of reasons. The most common reason was that the
patient had stopped attending the study clinic, due to program loss
to follow up (22%), transfer to another site (7%), or death (5%).
Study loss to follow up—patients who had made visits in the 12
months before data censoring but not been interviewed—was 8%.
Discontinuation of treatment may well be correlated with our
Figure 4. Probability of not feeling well on day prior to interview by time on ART.
doi:10.1371/journal.pone.0012731.g004
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average were more likely to drop out of treatment or avoid being
interviewed. Our results should therefore be interpreted as
conditional on staying alive and on treatment at the same site.
As indicated by the CD4 counts shown in Figure 2, however, the
study cohort does not appear to have substantially better or worse
immunological outcomes than the broader population of ART
patients at the largest study site.
Table 5. Reference probability, marginal effects, and duration of inability to perform normal activities in previous work week.
Variable Marginal effect
Probability or number
of days p-value
95% confidence interval
for marginal effect
Outcome: Unable to perform normal activities in previous week because of problems with physical or mental health
c
Reference case estimated probability =0.356
sex (male) 20.039 31.7% 0.164 [20.095,0.016]
18–29 years old 20.02 33.6% 0.466 [20.075,0.034]
40–49 years old 0.07 42.6% 0.034 [0.005,0.135]
50+ years old 0.033 38.9% 0.517 [20.067,0.133]
–90 to 21 days 0.140 49.6% 0.005 [0.041,0.240]
0 to 30 days (reference) * 35.6% * *
31–90 days 0.003 35.9% 0.949 [20.082,0.087]
91–180 days 20.09 26.6% 0.017 [20.163,20.016]
181–270 days 20.112 24.4% 0.005 [20.191,20.034]
271–360 days 20.15 20.6% 0.000 [20.227,20.073]
361–450 days 20.166 19.0% 0.000 [20.242,20.089]
451–540 days 20.152 20.4% 0.000 [20.230,20.073]
541–630 days 20.194 16.2% 0.000 [20.271,20.117]
631–720 days 20.200
b 15.6% 0.000 [20.275,20.126]
721–810 days 20.266 9.0% 0.000 [20.335,20.197]
811–900 days 20.241 11.5% 0.000 [–0.311,20.172]
901–990 days 20.265 9.1% 0.000 [20.333,20.197]
991–1080 days 20.243
a 11.3% 0.000 [20.312,20.175]
Outcome: Number of days unable to perform normal activities in previous week because of problems with physical or mental health if any inability in previous week
d
Reference case estimated number of days =3.036
sex (male) 20.001 3.303 0.994 [20.330,0.327]
18–29 years old 20.111 3.193 0.487 [20.426,0.203]
40–49 years old 0.054 3.358 0.759 [20.288,0.396]
50+ years old 0.092 3.396 0.735 [20.441,0.625]
290 to 21 days 0.543 3.847 0.046 [0.009,1.077]
0 to 30 days (reference) * 3.304 * *
31–90 days 0.089 3.393 0.734 [20.425,0.603]
91–180 days 0.09 3.394 0.719 [20.401,0.581]
181–270 days 0.567 3.871 0.046 [0.010,1.124]
271–360 days 0.745 4.049 0.015 [0.144,1.346]
361–450 days 0.437 3.741 0.161 [20.174,1.048]
451–540 days 0.36 3.664 0.252 [20.255,0.976]
541–630 days 0.16 3.464 0.649 [20.527,0.847]
631–720 days 20.056
a 3.248 0.869 [20.719,0.608]
721–810 days 0.122 3.426 0.751 [20.635,0.880]
811–900 days 20.174 3.130 0.600 [20.822,0.475]
901–990 days 0.05 3.354 0.889 [20.654,0.754]
991–1080 days 20.759
a 2.545 0.020 [21.400,20.118]
*Reference case is a female subject age 30–39, 0–30 days on ART.
aIndicates p-value #0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.
bIndicates p-value .0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.
cLogistic regression, population averaged model.
dLinear regression, population averaged model; marginal effect = linear regression coefficient.
doi:10.1371/journal.pone.0012731.t005
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which took place on days when patients presented voluntarily to
the study clinics. It is likely that some visits during which interviews
were conducted were due to patient condition, and not for routine
monitoring or drug pickup. The study sites’ records do not allow
us to distinguish clearly between routine and non-routine medical
Figure 5. Probability of being unable to perform normal activities last week and of employment by time on ART.
doi:10.1371/journal.pone.0012731.g005
Table 6. Reference probability and marginal effects of being employed at time of interview (logistic regression, population
averaged model).
Variable Marginal effect Probability p-value
95% confidence interval for
marginal effect
Outcome: Currently have a job
Reference case estimated probability =0.308
sex (male) 0.062 37.0% 0.070 [20.005,0.129]
18–29 years old 20.038 27.0% 0.214 [20.098,0.022]
40–49 years old 0.032 34.0% 0.390 [20.041,0.105]
50+ years old 0.023 33.1% 0.687 [20.091,0.138]
290 to 21 days 20.002 30.6% 0.942 [20.067,0.062]
0 to 30 days (reference) * 30.8% * *
31–90 days 20.029 27.9% 0.313 [20.085,0.027]
91–180 days 0.004 31.2% 0.880 [20.046,0.054]
181–270 days 20.009 29.9% 0.750 [20.062,0.045]
271–360 days 0.014 32.2% 0.609 [20.040,0.069]
361–450 days 0.028 33.6% 0.312 [20.026,0.083]
451–540 days 0.087 39.5% 0.003 [0.029,0.144]
541–630 days 0.14 44.8% 0.000 [0.081,0.199]
631–720 days 0.125
a 43.3% 0.000 [0.069,0.181]
721–810 days 0.121 42.9% 0.000 [0.067,0.174]
811–900 days 0.144 45.2% 0.000 [0.092,0.196]
901–990 days 0.172 48.0% 0.000 [0.120,0.224]
991–1080 days 0.155
a 46.3% 0.000 [0.103,0.206]
*Reference case is a female subject age 30–39, 0–30 days on ART.
aIndicates p-value #0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.
bIndicates p-value .0.05 for Wald test that marginal effect equals marginal effect for 271–360 days on ART.
doi:10.1371/journal.pone.0012731.t006
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patient condition, then our results could understate the average
benefits of treatment later in the study. Since study staff did not
approach patients who appeared visibly ill and unable to
participate in an interview, and because most interviews were
conducted during routine visits, we believe that this potential bias
is modest. On the other hand, decisions not to interview patients
who appeared visibly ill, which were infrequent but did occur,
could lead to a slight overestimate of the benefits of treatment.
In addition, we frequently had long and irregular gaps between
interviews, resulting in a very unbalanced data set and differing
numbers of observations among subjects followed for the same
overall length of time. This resulted largely from the irregularity of
routine patient visits to the study clinics and the difficulty of
locating and interviewing patients who present at unscheduled
times. Finally, as with any study that relies on self-reported
interview data, recall error is likely. We deliberately chose very
short recall periods (# 7 days) to minimize this risk, but we could
not eliminate entirely.
Our results are roughly consistent with those of several studies
that have reported only to 12 months after treatment initiation. In
the study in Cape Town, South Africa, for example, the
proportion of patients reporting no problems with usual activities
rose from 76% at baseline to 94% at 12 months.[9] Similarly, in
Uganda the prevalence of functional impairment declined from
50% to 7% after 12 months on ART.[17] In the only study we are
aware of that reports to two years, the probability of Kenyan
agricultural workers on ART experiencing bodily pain often in the
previous week fell from 24.3% at treatment initiation to 9.9% after
two years, while the probability of fatigue declined from 40.5% to
14.8%.[18] While the two-year probabilities in this study were
lower than in ours, the magnitude of the declines—roughly 60%—
is similar. What we were able to show is that these improvements
endure through at least the third year on treatment.
We conclude that patients who remain on ART in South Africa
experience large improvements in their ability to perform normal
activities, symptom prevalence, and employment potential and
that these improvements are sustained and for some outcomes
continue to increase over the first three years on ART. While we
have no way to know how our study subjects compare with HIV-
negative South Africans of comparable socioeconomic status, the
relatively low prevalence of self-reported inability to perform
normal activities and of symptoms, and the relatively high
employment rate after three years, suggest that ART patients,
assuming that they remain on treatment, are able to lead relatively
normal lives.
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